Jupiter Life Line: Big Bets, Big Stakes

Jupiter Life Line Hospitals is moving from a three-hospital regional chain to a much larger western India platform. The company’s plan is to double bed capacity to about 2,500 beds by CY29, up from around 1,048 beds as of March 2026, through new hospitals in Pune, Mira-Bhayandar and Dombivli. That makes the stock a clear growth story, but also a capex-heavy one. The core numbers are strong. In Q3FY25, revenue rose 17.6% year on year to Rs 3,206 million, EBITDA increased 21.2% to Rs 750 million, and adjusted PAT grew 19.8% to Rs 525 million. EBITDA margin improved to 23.4% from 22.7%, while blended occupancy stood at 65.7% and ARPOB reached Rs 61,750. These are healthy operating trends, not just headline expansion. The expansion plan is large. Jupiter had already added 78 beds at Indore on 1 Jan’25 for a capex of Rs 250 million, and the hospital then had 309 beds. It also planned a 200–220 bed first phase at Dombivli by Q1FY27, two new hospitals in Pune and Mira-Bhayandar, and about Rs 9 billion of capex for the next two hospitals, with a wider Rs 14–16 billion plan over CY27–29. For shareholders, this is attractive if execution stays strong. More beds, higher occupancy and better ARPOB can lift revenue and margins because hospitals become more efficient at scale. But the risk is equally real: new hospitals can lose money in the early phase, cash balances may fall, and debt may rise before the new capacity starts paying back. ICRA also noted that occupancy had softened to 61.9% in 9MFY26 from 67.5% a year earlier, even though ARPOB improved to Rs 66,800. So the stock looks valuable, but not cheap. Jupiter is a good shareholder story if investors are comfortable with execution risk, high capital spending and a few years of waiting before the full earnings benefit arrives.